<blockquote><span style="font-size:90%">Quote:<hr/>And still no true TLD (the comparison between the 2 main trial arms). </span><hr/></blockquote> <br /> <br /> This is not the true TLD. It's the old TLD. <br /> <br /> You know there will be an issue with pseudo-progression in the primary endpoint. The question is, did the treatment work so well (because that is what the psPD was indicative of) that the primary endpoint couldn't be proven as a result? <br /> <br /> If that secondary fourth end point is not stat sig, then that will be the reason. IMO, stuff like that is much more easily explained in a comprehensive peer-reviewed journal than in a company press release.